Onsdag 28 Oktober | 17:16:41 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Redeye Initiates Coverage of Ultimovacs

2022-04-04 07:45:00

Redeye initiates coverage of Ultimovacs, a Nordic biotech company developing therapeutic cancer vaccines, which we believe has delivered promising phase I efficacy data in malignant melanoma. We view the current share price as an attractive entry opportunity for long-term-oriented investors.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/